|Bid||8.85 x 3200|
|Ask||8.86 x 1200|
|Day's range||8.78 - 9.02|
|52-week range||3.14 - 9.20|
|Beta (5Y monthly)||1.55|
|PE ratio (TTM)||N/A|
|Earnings date||05 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||12.08|
NEW ORLEANS, September 10, 2021--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Kadmon Holdings, Inc. (NasdaqGS: KDMN) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Kadmon will receive only $9.50 in cash for each share of Kadmon that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whet
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.
NEW YORK, September 09, 2021--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kadmon Holdings, Inc. (NASDAQ: KDMN) to Sanofi for $9.50 per share in cash is fair to Kadmon shareholders.